Mostrar el registro sencillo del ítem

dc.contributor.authorRibeiro, Camila Tiefenseept_BR
dc.contributor.authorPeixoto, Daniel Oppermannpt_BR
dc.contributor.authorSilva, Lucas dos Santos dapt_BR
dc.contributor.authorGirardi, Carolina Saibropt_BR
dc.contributor.authorBrum, Pedro Ozoriopt_BR
dc.contributor.authorKessler, Flávio Gabriel Carazzapt_BR
dc.contributor.authorSomensi, Nauanapt_BR
dc.contributor.authorBehrens, Luiza Marques Pratespt_BR
dc.contributor.authorBittencourt, Reykla Ramonpt_BR
dc.contributor.authorSoares, Laissa Santospt_BR
dc.contributor.authorSilveira, Alexandre Kleberpt_BR
dc.contributor.authorOliveira, Jade dept_BR
dc.contributor.authorMoreira, Jose Claudio Fonsecapt_BR
dc.contributor.authorGasparotto, Jucianopt_BR
dc.contributor.authorGelain, Daniel Penspt_BR
dc.date.accessioned2021-12-07T04:31:23Zpt_BR
dc.date.issued2021pt_BR
dc.identifier.issn2666-3546pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/232655pt_BR
dc.description.abstractHSP70 is one of the main molecular chaperones involved in the cellular stress response. Besides its chaperone action, HSP70 also modulates the immune response. Increased susceptibility to toxic insults in intra- and extracellular environments has been associated with insufficient amounts of inducible HSP70 in adult neurons. On the other hand, exogenous HSP70 administration has demonstrated neuroprotective effects in experimental models of age-related disorders. In this regard, this study investigated the effects of exogenous HSP70 in an animal model of dopaminergic denervation of the nigrostriatal axis. After unilateral intrastriatal injection with 6-hydroxydopamine (6-OHDA), the animals received purified recombinant HSP70 through intranasal administration (2 μg/rat/day) for 15 days. Our results indicate a neuroprotective effect of intranasal HSP70 against dopaminergic denervation induced by 6-OHDA. Exogenous HSP70 improved motor impairment and reduced the loss of dopaminergic neurons caused by 6-OHDA. Moreover, HSP70 modulated neuroinflammatory response in the substantia nigra, an important event in Parkinson’s disease pathogenesis. Specifically, HSP70 treatment reduced microglial activation and astrogliosis induced by 6-OHDA, as well as IL-1β mRNA expression in this region. Also, recombinant HSP70 increased the protein content of HSP70 in the substantia nigra of rats that received 6-OHDA. These data suggest the neuroprotection of HSP70 against dopaminergic neurons damage after cellular stress. Finally, our results indicate that HSP70 neuroprotective action against 6-OHDA toxicity is related to inflammatory response modulation.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofBrain, behavior, & immunity - health. [New York]. Vol. 14 (July 2021), 100253, 11 p.pt_BR
dc.rightsOpen Accessen
dc.subjectProteínas de choque térmico HSP70pt_BR
dc.subjectExogenous HSP70en
dc.subjectDenervaçãopt_BR
dc.subjectIntranasal treatmenten
dc.subjectNeurônios dopaminérgicospt_BR
dc.subject6-OHDAen
dc.subjectOxidopaminapt_BR
dc.subjectNeuroprotectionen
dc.subjectNeuroproteçãopt_BR
dc.subjectNeuroinflammationen
dc.subjectNeurodegenerative diseasesen
dc.subjectDoença de Parkinsonpt_BR
dc.subjectParkinson’s diseaseen
dc.titleIntranasal HSP70 administration protects against dopaminergic denervation and modulates neuroinflammatory response in the 6-OHDA rat modelpt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb001134126pt_BR
dc.type.originEstrangeiropt_BR


Ficheros en el ítem

Thumbnail
   

Este ítem está licenciado en la Creative Commons License

Mostrar el registro sencillo del ítem